Cerebral sinus-venous thrombosis

Ida Martinelli, Serena Maria Passamonti, Elena Rossi, Valerio de Stefano

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cerebral sinus-venous thrombosis (CSVT) is a rare life-threatening disease with an estimated annual incidence of 3-4 cases per million in adults and 7 cases per million in neonates. Brain tumors, cerebral infections and traumas are local risk factors for CSVT, but the commonest encountered risk factors are oral contraceptive use, pregnancy and puerperium that make the disease predominant in female sex. In 15-20 % of patients, the disease remains unprovoked, i. e., occurring in the absence of predisposing factors. Thrombophilic abnormalities either inherited [deficiency of the natural anticoagulant proteins antithrombin, protein C or protein S, mutations in the factor V gene (factor V Leiden) or prothrombin gene (prothrombin G20210A)] or acquired (antiphospholipid antibodies) are worthy to be investigated in patients with CSVT, as well as hyperhomocysteinemia. In a small proportion of patients, CSVT is the first manifestation of a myeloproliferative neoplasm. The proportion of patients with recurrent CSVT is low, but venous thromboembolism (deep vein thrombosis in the lower limbs or pulmonary embolism) can develop particularly in patients with a first idiopathic CSVT. In the past decade, there has been increasing evidence that early diagnosis and anticoagulant treatment reduce morbidity of CSVT and improve survival. However, the optimal duration of anticoagulant treatment is not well established, because limited information is available on the rate of CSVT recurrence after anticoagulant discontinuation.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalInternal and Emergency Medicine
Volume7
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Intracranial Sinus Thrombosis
Venous Thrombosis
Anticoagulants
Prothrombin
Antithrombin Proteins
Hyperhomocysteinemia
Antiphospholipid Antibodies
Factor V
Protein S
Venous Thromboembolism
Oral Contraceptives
Protein C
Pulmonary Embolism
Brain Neoplasms
Causality
Postpartum Period
Genes
Early Diagnosis
Lower Extremity
Newborn Infant

Keywords

  • Anticoagulant therapy
  • Cerebral sinus
  • Risk factors
  • Thrombophilia
  • Venous thrombosis

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine

Cite this

Cerebral sinus-venous thrombosis. / Martinelli, Ida; Passamonti, Serena Maria; Rossi, Elena; de Stefano, Valerio.

In: Internal and Emergency Medicine, Vol. 7, No. SUPPL. 3, 10.2012, p. 221-225.

Research output: Contribution to journalArticle

Martinelli, Ida ; Passamonti, Serena Maria ; Rossi, Elena ; de Stefano, Valerio. / Cerebral sinus-venous thrombosis. In: Internal and Emergency Medicine. 2012 ; Vol. 7, No. SUPPL. 3. pp. 221-225.
@article{ec99762bcb6b4a7d9f2146d33a714b02,
title = "Cerebral sinus-venous thrombosis",
abstract = "Cerebral sinus-venous thrombosis (CSVT) is a rare life-threatening disease with an estimated annual incidence of 3-4 cases per million in adults and 7 cases per million in neonates. Brain tumors, cerebral infections and traumas are local risk factors for CSVT, but the commonest encountered risk factors are oral contraceptive use, pregnancy and puerperium that make the disease predominant in female sex. In 15-20 {\%} of patients, the disease remains unprovoked, i. e., occurring in the absence of predisposing factors. Thrombophilic abnormalities either inherited [deficiency of the natural anticoagulant proteins antithrombin, protein C or protein S, mutations in the factor V gene (factor V Leiden) or prothrombin gene (prothrombin G20210A)] or acquired (antiphospholipid antibodies) are worthy to be investigated in patients with CSVT, as well as hyperhomocysteinemia. In a small proportion of patients, CSVT is the first manifestation of a myeloproliferative neoplasm. The proportion of patients with recurrent CSVT is low, but venous thromboembolism (deep vein thrombosis in the lower limbs or pulmonary embolism) can develop particularly in patients with a first idiopathic CSVT. In the past decade, there has been increasing evidence that early diagnosis and anticoagulant treatment reduce morbidity of CSVT and improve survival. However, the optimal duration of anticoagulant treatment is not well established, because limited information is available on the rate of CSVT recurrence after anticoagulant discontinuation.",
keywords = "Anticoagulant therapy, Cerebral sinus, Risk factors, Thrombophilia, Venous thrombosis",
author = "Ida Martinelli and Passamonti, {Serena Maria} and Elena Rossi and {de Stefano}, Valerio",
year = "2012",
month = "10",
doi = "10.1007/s11739-012-0806-9",
language = "English",
volume = "7",
pages = "221--225",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Cerebral sinus-venous thrombosis

AU - Martinelli, Ida

AU - Passamonti, Serena Maria

AU - Rossi, Elena

AU - de Stefano, Valerio

PY - 2012/10

Y1 - 2012/10

N2 - Cerebral sinus-venous thrombosis (CSVT) is a rare life-threatening disease with an estimated annual incidence of 3-4 cases per million in adults and 7 cases per million in neonates. Brain tumors, cerebral infections and traumas are local risk factors for CSVT, but the commonest encountered risk factors are oral contraceptive use, pregnancy and puerperium that make the disease predominant in female sex. In 15-20 % of patients, the disease remains unprovoked, i. e., occurring in the absence of predisposing factors. Thrombophilic abnormalities either inherited [deficiency of the natural anticoagulant proteins antithrombin, protein C or protein S, mutations in the factor V gene (factor V Leiden) or prothrombin gene (prothrombin G20210A)] or acquired (antiphospholipid antibodies) are worthy to be investigated in patients with CSVT, as well as hyperhomocysteinemia. In a small proportion of patients, CSVT is the first manifestation of a myeloproliferative neoplasm. The proportion of patients with recurrent CSVT is low, but venous thromboembolism (deep vein thrombosis in the lower limbs or pulmonary embolism) can develop particularly in patients with a first idiopathic CSVT. In the past decade, there has been increasing evidence that early diagnosis and anticoagulant treatment reduce morbidity of CSVT and improve survival. However, the optimal duration of anticoagulant treatment is not well established, because limited information is available on the rate of CSVT recurrence after anticoagulant discontinuation.

AB - Cerebral sinus-venous thrombosis (CSVT) is a rare life-threatening disease with an estimated annual incidence of 3-4 cases per million in adults and 7 cases per million in neonates. Brain tumors, cerebral infections and traumas are local risk factors for CSVT, but the commonest encountered risk factors are oral contraceptive use, pregnancy and puerperium that make the disease predominant in female sex. In 15-20 % of patients, the disease remains unprovoked, i. e., occurring in the absence of predisposing factors. Thrombophilic abnormalities either inherited [deficiency of the natural anticoagulant proteins antithrombin, protein C or protein S, mutations in the factor V gene (factor V Leiden) or prothrombin gene (prothrombin G20210A)] or acquired (antiphospholipid antibodies) are worthy to be investigated in patients with CSVT, as well as hyperhomocysteinemia. In a small proportion of patients, CSVT is the first manifestation of a myeloproliferative neoplasm. The proportion of patients with recurrent CSVT is low, but venous thromboembolism (deep vein thrombosis in the lower limbs or pulmonary embolism) can develop particularly in patients with a first idiopathic CSVT. In the past decade, there has been increasing evidence that early diagnosis and anticoagulant treatment reduce morbidity of CSVT and improve survival. However, the optimal duration of anticoagulant treatment is not well established, because limited information is available on the rate of CSVT recurrence after anticoagulant discontinuation.

KW - Anticoagulant therapy

KW - Cerebral sinus

KW - Risk factors

KW - Thrombophilia

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84867723837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867723837&partnerID=8YFLogxK

U2 - 10.1007/s11739-012-0806-9

DO - 10.1007/s11739-012-0806-9

M3 - Article

C2 - 23073861

AN - SCOPUS:84867723837

VL - 7

SP - 221

EP - 225

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - SUPPL. 3

ER -